Karyopharm bone marrowcancer combination selected for top EHA presentation

Karyopharm Therapeutics (NASDAQ:KPTI) announced that its late-breaking Phase 3 SENTRY clinical trial data has been selected for an oral presentation at the European Hematology Association (EHA) 2026 Congress, placing the treatment among the top six late-breaking abstracts at the event.

The pivotal study evaluated the safety and efficacy of Karyopharm's lead asset, selinexor, when administered in combination with the standard-of-care medication ruxolitinib in patients with medical-treatment-naive myelofibrosis—a rare and aggressive type of bone marrow cancer that disrupts the body's normal blood cell production.

Data from the trial demonstrated that the combination regimen delivered rapid, deep, and sustained spleen volume reductions alongside comparable symptom improvements for patients.

Furthermore, the combination therapy achieved a promising overall survival signal and resulted in higher rates of variant allele frequency reductions of a 20% threshold or greater by week 24 of treatment, indicating potential disease-modifying capabilities.

Management noted that the safety profile of the combined therapy remained manageable throughout the evaluation period.

To further validate the clinical findings, a separate post-hoc analysis tracking 24 patients from the earlier Phase 1 portion of the study was conducted.

The results suggest that achieving a 35% reduction in spleen volume, a standard clinical metric known as SVR35, may serve as a reliable predictor for improved overall survival in this patient population.

The complete Phase 3 SENTRY data set is scheduled for official presentation on June 14, 2026, at the EHA Congress in Stockholm, Sweden.

Ahead of the oral session, the peer-reviewed clinical findings have been published in the Journal of Clinical Oncology, providing early medical community access to the detailed efficacy and safety parameters of the combination trial.